Ruti Aga's Six-Year Ban: The 2+4 Arithmetic, a Forged Prescription, and a Misidentified Substance

Six years. Two for a substance that has no proven performance benefit in marathon running, and four for a piece of paper that turned out to be more dangerous than the substance itself. Reading the Ruti Aga case, my first question was not what she took — it was why the half-marathon time is missing from the report. She won a half marathon in China in March, an in-competition test came back positive, and the Athletics Integrity Unit (AIU) announced a six-year ban on Thursday. But the substance being called a ‘prohibited steroid’ in media reports is not a steroid. Methylprednisolone is a glucocorticoid — WADA Prohibited List class S9 — and it is prohibited only in-competition, by injection, oral or rectal routes. That technical distinction is the centre of the case. I opened the spreadsheet before the StubHub Center press box filled with noise; the habit stuck. I parsed the AIU statement line by line, and what emerged is a case where the real violation is not the drug but the document. Aga is 32. The depth in Ethiopian women's marathon is such that a 2:18–2:20 performer cannot be assured of a national-team place. Her record includes the 2026 Tokyo Marathon title and three second-place finishes at World Marathon Majors — a genuinely elite marathoner, but one whose career was on a plateau, not a peak. I watched the 2026 Tokyo Marathon from a Los Angeles desk, timestamping every 5km split; that day Aga's strength was pacing, not sprinting. The half marathon she won in China in March appears in the Stage-1 report without a name, without a time, without field strength. For a performance analyst, that is an uncomfortable hole. But in this case performance is secondary. The primary fact is that the race had an in-competition test, the sample was positive, and the sample contained methylprednisolone. Under the stopwatch, every salary line becomes a performance claim — especially when a knee injury and an appearance fee land in the same sentence. Under the 2026 WADA Prohibited List, S9 glucocorticoids are prohibited only in-competition — by injection, oral or rectal route. That matters because a road race's in-competition testing window opens at 23:59 the day before the race. An intra-articular knee injection, standard sports-medicine practice for knee synovitis in distance runners, can leave residues that are caught in-competition if given days earlier. So the case is not about ‘steroid use’; it is about route and timing. And Aga had room for a technical defence — if she had genuine medical records, a TUE, or correct washout timing. According to the AIU statement, she did the opposite: she cited a knee injury, but the prescription was forged. The sanction arithmetic is simple: two years for the presence violation, four years for tampering. 2+4=6. That arithmetic tells us the panel rejected the no-significant-fault mitigation that could have reduced the presence sanction. The four-year tampering sanction is the Code's standard provision, but it was activated — meaning the panel found a forged prescription and misleading statements during the investigation. According to the AIU, the four years came from an interview, not from the document alone. The case began as document verification and became graver because of what was said. The forged-prescription chain has three independent verification failures. First, the prescription was written by a ‘doctor’ who was a family member and had no medical registration. Second, the clinic named on the prescription did not exist. Third, the person claimed to have used ‘an old prescription pad from a former workplace’ — and the clinic explicitly disowned any such pad. Three checkpoints, three document failures. This is not a filing error; it is the signature of medical support without a credentialed team physician. There is no mention of a TUE in Aga's case, and a genuine treatment would have been defended with genuine records. The forged prescription is evidence that the paperwork needed for a defence did not exist — or was never there. Here is the hardest fact in the case: S9 glucocorticoids are prohibited only in-competition. An athlete who took a knee injection and observed the correct washout period could have been entirely clean. One who took the injection and got the timing wrong could have argued no-fault or a reduced sanction. But one who took the injection, got the timing wrong, and then forged the prescription destroyed her only legal path. The six-year ban prices the lie that tried to save the drug, not the drug itself. The model is clean; the incentive underneath it is what I interrogate — and the incentive here was clear: for an injured marathoner, the pressure to mask pain comes from the appearance-fee economy. Glucocorticoids are the cheapest, most available tool; the medical network around them is informal. In career-value terms, the ban starts on 10 September — the same date as her provisional suspension. Six years later she will be nearly 38. In Ethiopian women's marathon depth, a 38-year-old returnee with a doping record is effectively unselectable. The ban is six years on paper; in practice it is career death. Her 2026 Tokyo title and three Major second places survive unless the panel finds earlier use — the report does not state the disqualification scope. But the March Chinese half marathon result and prize money should be treated as annulled under standard AIU practice, even if the statement does not say so. That is an inference, and I am logging it as one. The real systemic story is in China's label-race circuit. Large appearance fees, deep East African elite fields, and AIU testing are colliding in the same races. That circuit used to be a lucrative, low-risk income tier for East African marathoners between Majors. It is now the AIU's highest-yield testing ground. The appearance-fee economy and the testing economy are converging. The next enforcement frontier is sample analysis and document verification. The AIU now has a queue of cases where the first violation was the substance and the second was the paper used to explain it. This is not an outlier; it belongs to a recognisable family — East African road-racing cases where an initial substance violation is compounded by a fabricated or altered explanation. I do not trust a trend until I can reconcile it to the ledger — and here the ledger has two columns: the sample and the paper. The media error needs to be logged too. Several reports called methylprednisolone a ‘prohibited steroid’ and even said WADA classes it as performance enhancing. That is technically wrong. Glucocorticoids are anti-inflammatory, not anabolic steroids. S1 covers anabolic steroids; S9 covers glucocorticoids. Putting them in the same box misreads the case — it invites comparison with an anabolic-steroid case when the issue is route and timing. If you erase that distinction, you cannot understand why Aga had a defence at all. The only girl in the press box had a spreadsheet and no patience for noise — and the noise buried the technical error. The contrarian angle is that this is not a doping case; it is a document-verification case. The six-year ban is not for the drug, which has no proven benefit for marathon performance; it is for the lie told to save the drug. With a competent defence — genuine medical records, correct route, correct timing, perhaps a TUE — this could have ended with a reprimand or a much shorter sanction, and no tampering charge at all. So the question is not whether the AIU is strict. The question is why a 32-year-old elite runner did not have a credentialed team physician. The answer is economic. In East African road running, medical support often comes from informal networks, and the same network can end a career with a forged prescription. The sanction is individual, but the structure is collective. And until that structure changes, the next runner will do the same arithmetic: mask the pain, take the injection, and if caught, handle the paper. Aga's case shows the price of that arithmetic — but it also shows the arithmetic is still the same. What to watch? The CAS appeal window is typically about 21 days from the reasoned decision; the forged-prescription finding is document-based and hard to overturn. The formal annulment of the March race result and prize money is still to be announced. Watch whether the AIU investigates the role of an agent or management beyond the family-member ‘doctor’ — the statement names only the family member. And most importantly, watch the silence of the Ethiopian federation. When a former Major winner gets six years and the national federation issues no statement, that silence is a data point too. For me, the lesson is that the athlete who used the drug as an excuse received a harsher sentence than the drug itself, because the drug's defence runs on paper and the paper was forged. When the next AIU statement lands, I will be looking at the same thing: how many other prescriptions are sitting in the same filing cabinet, from clinics that never existed.